tbuckley/cabot-search huggingface dataset:
HOUT-13. PATIENT REPORTED OUTCOME MEASURES IN BRAIN METASTASES PATIENTS – A SYSTEMATIC REVIEW
Authors: Anouk van Westrhenen, Aislyn DiRisio, Maya Harary, Eman Nassr, Anastasia Ermakova, Timothy Smith, Rania Mekary, Marike Broekman
Journal: Neuro-Oncology (2017)

Brain metastases (BMs) represent an important health care problem, with increasing incidence rates over time. Due to the heterogeneity of patient and tumor characteristics, it is hard to find consensus on optimal treatment strategy. Especially in palliative care, it is important to measure treatment effects on quality of life (QOL) from the patients’ perspective. Patient reported outcome measures (PROMs) can facilitate optimal treatment choice and even improve outcome in BMs patients. The aim of this review was to systematically analyze implementation and validity of different PROMs in BMs patients. PubMed, Embase, and Cochrane databases were systematically searched for studies on PROMs in patients with BMs. Study selection, data extraction, and quality assessment were performed independently by two investigators. Quality of PRO reporting was determined using the ISOQOL-recommended PRO reporting standards and each questionnaire was assessed using the Consensus-based Standards for the selection of health Measurement Instruments (COSMIN) grading criteria. In total, 53 studies were included, comprising 5358 patients with primary tumor types: lung (61%), breast (16%), gastrointestinal (4%), renal (3%), melanoma (2%), urogenital (2%), other (8%), and unknown (4%). Nine different PROMs were applied, ranging from general cancer (FACT-G, EORTC-QLQ-C15-PAL, ESAS, SF-36, McGill QOL, EuroQol-5D) to brain specific (FACT-Br, BASIQ, EORTC-QLQ-BN20) questionnaires. Half of the general cancer questionnaires (n=3) were not validated among BM patients. According to a predefined cut-off point in line with previous work, 22 studies had insufficient quality of PRO reporting. A variety of PROMs are used in BM patients, including questionnaires intended for general cancer and general patient populations, which have not been validated in patients with BMs. Given the unique clinical considerations in patients with brain metastases, our results indicate the need for a standardized and validated questionnaire with high level of reporting for BM patients.
RTHP-10. IMPACT OF COMBINATION IMMUNOTHERAPY WITH TUMOR TREATING FIELDS THERAPY IN A GLIOMA COHORT
Authors: Jessica Schulte, Yazmin Odia, Laura Donovan, Fabio Iwamoto
Journal: Neuro-Oncology (2017)

Tumor-treating fields (TTF) increase patient survival in glioblastoma, and are approved for recurrent (2011) and de novotumors (2016). Since 2012, 52 patients with gliomas at Columbia University were treated with TTF. Given preclinical data suggesting synergy between TTF and PD1-targeted therapy, the rates and outcomes of combination TTF and immunotherapy were analyzed. Of 52 patients, 40% were women. Median age at diagnosis was 58 (23-84) years. WHO glioma grade was II (6%), III (10%), or IV (84% of patients). TTF was used at recurrence in 42 (81%), with 0-4 prior recurrences. Prior therapy included bevacizumab (20%), resection (gross-total in 54%), radiation (60Gy in 85%), and temozolomide (100%). 11 (75%) patients met a compliance goal of 75%. Only 2 (4%) experienced skin toxicity requiring interruption. Concurrent systemic therapy included temozolomide (31%), nitrosourea (8%), bevacizumab (37%), or immunotherapy (54% of patients). At interim follow-up, progression free (PFS) and overall (OS) survival were 3.6 and 21.5 months, respectively. Objective response rate (ORR) based on RANO was increased in patients treated with concurrent immunotherapy (26% vs. 13%). Among GBM patients treated with concurrent immunotherapy, median PFS was significantly increased (4.6 vs. 3.5 mo, p=0.04), and survival trended upward (8.3 vs. 6.5 mo, p=0.32). After long-term follow-up, PFS, OS, and impact of compliance rates will be re-analysed. TTF improves survival for glioblastoma patients and immunotherapy shows promise in other cancers. The possible synergy between these modalities in preclinical studies and this retrospective series warrants further study in a randomized controlled trial. We propose a single-arm phase II trial of concurrent PD1 inhibitor and TTF for patients with bevacizumab-naïve glioblastoma, at diagnosis or recurrence. OS is the primary endpoint; secondary endpoints include PFS, ORR, and predictive value of PDL1 expression, and impact of compliance. Results from the EF-14 trial will serve as a historical control.
Frontal Fibrosing Alopecia—The Fashion of the Renaissance
Authors: Gianluca Nazzaro, Stefano Veraldi
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
P1.08-006 Phase I/II Study of Carboplatin, nab-paclitaxel, and Concurrent Radiation Therapy for Patients with Locally Advanced NSCLC
Authors: Y. Kawano, H. Yamaguchi, K. Hirano, A. Horiike, M. Satouchi, S. Hosokawa, R. Morinaga, K. Komiya, K. Inoue, Y. Fujita, M. Takenoyama, T. Kimura, M. Okuno, Y. Hisamatsu, J. Kishimoto, T. Sasaki, Y. Nakanishi, I. Okamoto
Journal: Journal of Thoracic Oncology (2017)
RTHP-26. FEASIBILITY OF A CONCOMITANT ADMINISTRATION OF ALTERNATING ELECTRIC FIELDS AND RADIOTHERAPY – A PLANNING STUDY
Authors: Christoph Straube, Markus Oechsner, Severin Kampfer, Sophia Scharl, Friederike Schmidt-Graf, Jan Wilkens, Stephanie Combs
Journal: Neuro-Oncology (2017)

Tumor-Treating fields (TTF) is a novel treatment strategy for glioblastoma (GBM) that is currently approved for the use concomitantly to adjuvant chemotherapy. Preclinical data suggest a synergistic interaction of TTF and radiotherapy (RT). However, the dosimetric uncertainties caused by the highly dense arrays have led to caution of applying the TTF setup during RT. In a RW3 plate phantom we compared MV-and kV-CT based planned dose with the measured dose. After validating the accuracy of MV-CT based planning, VMAT-Plans where optimized on MV-CTs of an Alderson head phantom without TTF arrays. These plans were re-calculated on the same phantom equipped with TTF arrays. Dose at organs at risk (OAR) and target volumes (PTVs) were compared. The image quality of kV-CT, CBCT and MV-CT of the Alderson head phantom with TTF array were compared. Measurements of the RW3 plate phantom show a mean attenuation of 4.46% within a depth of 5 cm which is in-line with a MV-CT based calculated attenuation by 2.64% but not with kV-CT based planning which suggests an attenuation by 11.98%. MV-CT based VMAT planning and re-calculation reveals, that the conformity as well as the dose at organs at risk (OAR) are only slightly effected by the presence of TTF arrays. MV-CTs do not show any relevant artefacts and thus allow sufficient dose calculations without additional assumptions. In contrast, the imaging quality is largely effected by the arrays when kV-CTs and CBCTs are used due to strong artefacts which can lead to misassumptions of the dose distribution. MV-CT based planning and re-calculations reveals only insignificant interactions between the TTF arrays and dose application. Thus, daily replacement of NovoTTF arrays seems not to be necessary and RT is feasible, when the treatment plan is optimized to an array free planning CT.
2017 American Heart Association Focused Update on Adult Basic Life Support and Cardiopulmonary Resuscitation Quality: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care
Authors: Monica E. Kleinman, Zachary D. Goldberger, Thomas Rea, Robert A. Swor, Bentley J. Bobrow, Erin E. Brennan, Mark Terry, Robin Hemphill, Raúl J. Gazmuri, Mary Fran Hazinski, Andrew H. Travers
Journal: Circulation (2017)

Cardiopulmonary resuscitation is a lifesaving technique for victims of sudden cardiac arrest. Despite advances in resuscitation science, basic life support remains a critical factor in determining outcomes. The American Heart Association recommendations for adult basic life support incorporate the most recently published evidence and serve as the basis for education and training for laypeople and healthcare providers who perform cardiopulmonary resuscitation.
Prophylactic use of antiemetics for prevention of opioid-induced nausea and vomiting: a web based online survey among Italian experts on supportive care in cancer
Authors: R. Giusti, G. Daniele, H. Tsukuura, L. Verna, P. Marchetti, C. Ficorella, G. Porzio
Journal: Annals of Oncology (2017)
SCDT-48. CONVECTION-ENHANCED DELIVERY OF CETUXIMAB CONJUGATED IRON-OXIDE NANOPARTICLES FOR TREATMENT OF SPONTANEOUS CANINE INTRACRANIAL GLIOMAS
Authors: A Courtenay Freeman, Simon R Platt, Kelsey Robinson, Elizabeth Howerth, Joe Eagleson, Alexandros Bouras, Milota Kaluzova, Costantinos G Hadjipanayis
Journal: Neuro-Oncology (2017)

Cetuximab conjugated iron-oxide nanoparticles (cetuximab-IONPs) have shown both in-vitro and in-vivo anti-tumor efficacy against gliomas. The purpose of this pilot study was to evaluate the safety and potential efficacy of cetuximab-IONPs for treatment of spontaneously occurring intracranial gliomas in canines after convection-enhanced delivery (CED). The use of CED allowed for direct infusion of the cetuximab-IONPs both intratumorally and peritumorally avoiding the blood brain barrier (BBB) and limiting systemic effects. A total of 8 dogs participated in the study and only 2 developed mild post-operative complications, which resolved with medical therapy. All canines underwent a single CED treatment of the cetuximab-IONPs over 3 days awake and did not receive any further adjuvant treatments. Volumetric analysis showed a median reduction in tumor size of 54.9 % by MRI at one-month follow-up. Five dogs were euthanized due to recurrence of neurological signs other than seizures, two due to recurrent seizures, and one dog died in his sleep. Median survival time (MST) after surgery was 248 days (mean 367 days).
P3.02-076 Glutaminase Inhibitor CB-839 Radiosensitizes KRAS-Mutant Lung Cancer Cells in a LKB1- and KEAP1/NRF2-Pathway Dependent Manner
Authors: P. Sitthideatphaiboon, Q. Xiao, U. Giri, J. Heymach
Journal: Journal of Thoracic Oncology (2017)
P2.01-001 Serum Albumin Level Predicts the Survival Benefit of Chemotherapy in Elderly Advanced NSCLC Patients with Poor Performance Status
Authors: S. Ikeda, H. Yoshioka, S. Ikeo, M. Morita, N. Sone, T. Niwa, A. Nishiyama, T. Yokoyama, A. Sekine, T. Ogura, T. Ishida
Journal: Journal of Thoracic Oncology (2017)
Estrogen influence on lectin binding in Ca Ski cervical tumors cells.
Authors: Gail Y. McClure, Stewart L. Macleod, Justin B. Hill, Joseph S. Stanley, Thomas Kieber-Emmons
Journal: Cancer Research (2004)

3409  Studies of metastatic rates in cervical cancer patients have shown a relationship between hormonal levels and factors influencing metastatic propensity such as metalloproteinase, cycloxygenase and vascular endothelial growth factor activity. While these enzymes and growth factors may influence angiogensis and invasion into distant tissues, hormonal influence on additional factors directly influencing tumor cell binding properties may also modulate metastatic potential. Changes in tumor cell surface glycosylation are some of the most frequent biochemical alterations associated with metastatic potential. The Thomsen-Friedenriech antigen (TF), a galactosyl β1,3 N-Acetylgalactosamine (Galβ1,3GalNAc) moiety, is a tumor antigen common on cervical tumor lines and has been shown to be present in sialylated and non-sialylated forms in squamous cervical lesions metastatic to lymph nodes. To determine the influence of hormonal levels which modulate expression of cell surface oligosaccharides, we exposed Ca Ski cervical tumor cells to varying hormonal levels and hormonal combinations. Peanut agglutinin (PNA), a lectin specific for β–Gal residues but not sialylated moieties, as well as Jacalin fruit (JAC) and Amaranth lectin (ACA), which will bind sialylated and nonsialylated galactose residues preferential for GalNAc and β-Gal respectively, were used in FACS assays to assess surface expression of these structures following hormonal treatments. All hormonally treated Ca Ski cells showed increased TF binding compared to nontreated controls. Since low estrogen has been suggested to enhance terminal sialylation of oligosaccharide attachments, we assessed sialylation using PNA, ACA and JAC binding on cervical tumor cells cultured with varying doses of estradiol. PNA binding indicated that greater binding of non-sialylated oligosaccharides occurred with increasing doses of estradiol. Additionally, in ACA and JAC, which will bind sialylated structures, an inverse relationship between binding levels and estradiol dose was observed. Overall, these assays indicate that although TF antigen increases with estradiol dose, sialylation decreases in estrogen treated CA Ski cells. Such data suggest that the hormonal status of the patient may influence the sialylation of such tumor cells and the specific oligosaccharides moieties related to metastasis. Sialyltransferase enzymes are currently being assessed to determine the effects of hormones on expression levels of specific enzymes which may influence cell surface oligosaccharide antigen presentation.
MA 11.07 Exosomes-Transmitted MicroRNAs Promote EGFR-TKIs Resistance in NSCLC by Activating PI3K/AKT Signaling Pathway
Authors: X. Liu, T. Jiang, X. Li, J. Li, L. Zhang, S. Zhao, Y. Jia, J. Shi, C. Zhao, M. Qiao, F. Zhou, J. Zhao, C. Zhou
Journal: Journal of Thoracic Oncology (2017)
MA 15.08 Safety and Efficacy of Osimertinib in Treating an EGFR-Mutant Lung Cancer Patient with a Germline EGFR T790M Mutation
Authors: W. Ma, J. Gong, J. Shan, D. Lewis, W. Xiao, J. Hung, E.H. Moore, Y. Zhang, N.Z. Mans, J. Welborn, K.S. Lam, T. Li
Journal: Journal of Thoracic Oncology (2017)
Vigilancia de infecciones por E. coli enterohemorrágico (ECEH) y del síndrome hemolítico urémico (SHU) en Europa
Authors: A Ammon
Journal: Eurosurveillance (1997)

Desde su primera descripcion (1), las cepas Escherichia coli O157: H7 y otras E. coli enterohemorragicas (ECEH) son conocidas por ser los principales agentes infecciosos responsables de colitis hemorragica. Estas E. coli elaboran una o mas shiga-toxinas (stx) o Vero citotoxinas Vero. En sentido estricto, el termino ECEH se refiere exclusivamente a los serotipos causantes de una enfermedad clinica similar a la ocasionada por E. coli O157:H7, aunque no existe una definicion generalizada sobre cuando una E. coli productora de stx se considera ECEH.
CSIG-17. TARGETING THE KYNURENINE PATHWAY OF TRYPTOPHAN METABOLISM IN PATIENT-DERIVED MELANOMA BRAIN METASTATIC CELLS
Authors: Hassan A Fadel, Sharon K Michelhaugh, Anthony R Guastella, Sam Kiousis, Sandeep Mittal
Journal: Neuro-Oncology (2017)

Proportionate to their incidence, melanoma lesions have the greatest propensity to form brain metastases. A paucity of treatment options for metastatic brain tumors has led to poor patient prognosis and a dire need for novel therapies. Mounting evidence favors that the kynurenine pathway (KP) of tryptophan metabolism promotes an immunosuppressive tumor microenvironment thereby contributing to the pathogenesis of primary brain tumors, however, the role of tryptophan metabolism is unknown in melanoma brain metastases. In this study, we evaluated the effects of targeting the rate-limiting enzymes of the KP, as well as the aryl hydrocarbon receptor (AhR) (a downstream effector of KP metabolites). Patient tumor tissue acquired following microsurgical resection was used to generate patient and matching xenograft mouse model cell lines. Immunocytochemical (ICC) staining of the patient and mouse cells was performed using antibodies specific for human indoleamine 2,3-dioxygenase (IDO)1, IDO2, tryptophan 2,3-dioxygenase (TDO)2, and AhR. Dose-response curves were performed in vitro, ranging from 1nM to 100µM, with small molecule inhibitors for IDO1 (epacadostat), IDO2 (tenatoprazole), TDO2 (680C91), and AhR (CH223191). Cell proliferation was measured via MTT assay. Cells were also treated with interferon-gamma to upregulate IDO1. ICC staining validated the presence of the KP, and displayed analogous staining in both cell lines. Tenatoprazole, 68C091, and CH223191 demonstrated negative correlations between drug concentration and proliferation (Pearson r= -0.974; -0.950; -0.865; respectively, p<0.03 for all) with the highest concentrations reducing proliferation to 45.6, 53.5, and 54.9% control, respectively. No correlation was found for epacadostat treatment. Interferon-gamma pre-treatment did not alter epacadostat response. IDO2 and TDO2 play a greater role than IDO1 in driving the KP in melanoma brain metastatic cells. With the expression of multiple tryptophan converting enzymes in the same cells, the downstream target AhR may be the more logical therapeutic target for future treatment strategies.
A Test-and-Not-Treat Strategy for Onchocerciasis in<i>Loa loa</i>–Endemic Areas
Authors: Joseph Kamgno, Sébastien D. Pion, Cédric B. Chesnais, Matthew H. Bakalar, Michael V. D’Ambrosio, Charles D. Mackenzie, Hugues C. Nana-Djeunga, Raceline Gounoue-Kamkumo, Guy-Roger Njitchouang, Philippe Nwane, Jules B. Tchatchueng-Mbouga, Samuel Wanji, Wilma A. Stolk, Daniel A. Fletcher, Amy D. Klion, Thomas B. Nutman, Michel Boussinesq
Journal: New England Journal of Medicine (2017)

Implementation of an ivermectin-based community treatment strategy for the elimination of onchocerciasis or lymphatic filariasis has been delayed in Central Africa because of the occurrence of serious adverse events, including death, in persons with high levels of circulating Loa loa microfilariae. The LoaScope, a field-friendly diagnostic tool to quantify L. loa microfilariae in peripheral blood, enables rapid, point-of-care identification of persons at risk for serious adverse events.A test-and-not-treat strategy was used in the approach to ivermectin treatment in the Okola health district in Cameroon, where the distribution of ivermectin was halted in 1999 after the occurrence of fatal events related to L. loa infection. The LoaScope was used to identify persons with an L. loa microfilarial density greater than 20,000 microfilariae per milliliter of blood, who were considered to be at risk for serious adverse events, and exclude them from ivermectin distribution. Active surveillance for posttreatment adverse events was performed daily for 6 days.From August through October 2015, a total of 16,259 of 22,842 persons 5 years of age or older (71.2% of the target population) were tested for L. loa microfilaremia. Among the participants who underwent testing, a total of 15,522 (95.5%) received ivermectin, 340 (2.1%) were excluded from ivermectin distribution because of an L. loa microfilarial density above the risk threshold, and 397 (2.4%) were excluded because of pregnancy or illness. No serious adverse events were observed. Nonserious adverse events were recorded in 934 participants, most of whom (67.5%) had no detectable L. loa microfilariae.The LoaScope-based test-and-not-treat strategy enabled the reimplementation of community-wide ivermectin distribution in a heretofore "off limits" health district in Cameroon and is a potentially practical approach to larger-scale ivermectin treatment for lymphatic filariasis and onchocerciasis in areas where L. loa infection is endemic. (Funded by the Bill and Melinda Gates Foundation and others.).
Delays in seeking treatment far symptoms: A dilemma in the care of heart failure patients
Authors: LS Evangelista, LV Doering, KA Dracup
Journal: Circulation (1999)

Delays in Seeking Treatment for Symptoms: A Dilemma in the Care of Heart Failure Patients Lorraine S Evangelista, UCLA, Los Angeles, CA; Lynn V Doering, Kathleen A Dracup. UCLA Sch of Nursing, Los Angeles, CA Delays in seeking medical care for heart failure (HF) symptoms may influence patient outcomes. However, the health-care seeking patterns of HF patients are not well understood. METHODS: A retrospective chart review of all patients admitted with HF at a VA facility was conducted to 1) describe the delay time between symptom onset and hospital admission; 2) examine whether previous HF hosprtalizations reduced delay time tor seeking treatment for subsequent HF admissions; and 3) assess the most common symptoms experienced by HF patients. Relationships between delay in seeking treatment for symptoms, sociodemographic variables, and clinical presentation were assessed using univariate and multivariate analyses. RESULTS: The sample consisted of 753 patients. The mean delay time (range O [<24hours]- 5 (2:5 days]) between symptom onset and the index hospital admission was 2.93 + .68 days. Delay time decreased to 1.86+ .93 days tor the second admission (N = 220), 1.47±.57 days for the third admission (N = 89), 1.33 ± .13 days for the fourth admission (N = 45) and 1.21 + . 92 days for the fifth admission (N = 19). The most common symptoms on admission were· dyspnea (76°/o), edema (66%). fatigue (37%) and angina (25%). In a multivariate model, dyspnea and edema were associated with increased delay (r = .332, p < .000, r::;: .4241 p< .000 respectively), while angina was related to decreased delay (r = .403, p < .000). CONCLUSION: Although previous hospitalization with HF decreased delay time between symptom onset and hospital admission, the delays in seeking treatment tor HF symptoms remained significantly high. This study supports the need for interventions that will increase ear1y symptom recognition and management on the part of patients and their families which may reduce delay in seeking treatment for symptoms and consequently improve patient outcomes.
MA 08.02 Efficacy of Single-Dose NEPA versus 3-Day Aprepitant Regimen for Prevention of CINV: A Phase 3 Lung Cancer Subset Analysis
Authors: S. Lu, L. Zhang, A. Dechaphunkul, C. Lanzarotti, K. Jordan, M. Aapro
Journal: Journal of Thoracic Oncology (2017)
P2.02-038 Imaging Platform for the Quantification of Cell-Cell Spatial Organization within the Tumor-Immune Microenvironment
Authors: K. Enfield, S. Martin, V. Martinez, S. Kung, P. Gallagher, K. Milne, Z. Chen, S. Lam, J.C. English, C. Macaulay, M. Guillaud, W. Lam
Journal: Journal of Thoracic Oncology (2017)